Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey
نویسندگان
چکیده
منابع مشابه
AB030. Evolution of phosphodiesterase type 5 inhibitors
After launching of sildenafil citrate, the last invention of 20 century, in 1998, oral phosphodiesterase type 5 (PDE5) inhibitor has been established as first line treatment of erectile dysfunction and shift new paradigm of diagnosis and treatment of erectile dysfunction. The big success of sildenafil in pharmaceutical R&D induced the consecutive development of the so-called ‘The second Viagra’...
متن کاملPhosphodiesterase type 5 inhibitors for erectile dysfunction.
The cyclic nucleotide signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical pr...
متن کاملUse of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
PURPOSE Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer. MATERIALS AND METHODS The study was comprised of 4,752 consecutive patients wit...
متن کاملPhosphodiesterase type 5 inhibitors: back and forward from cardiac indications.
PDE5 inhibitors (PDE5i) are widely known as treatment for erectile dysfunction (ED). This favorable action has emerged as a "side effect" from pioneering studies when PDE5i have been originally proposed as treatment for coronary artery disease (CAD). PDE5i showed marginal benefits for CAD treatment; although disappointing for that indication, they improved systemic and pulmonary vasodilation an...
متن کاملPhosphodiesterase type 5 inhibitors and sudden sensorineural hearing loss.
UNLABELLED Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss. OBJECTIVE To present two patients with sudden deafness developed after an occasional use of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and sudden hearing loss. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Impotence Research
سال: 2003
ISSN: 0955-9930,1476-5489
DOI: 10.1038/sj.ijir.3901067